Sawynok Jana
From the Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada.
Anesth Analg. 2014 Jul;119(1):170-178. doi: 10.1213/ANE.0000000000000246.
Ketamine, in subanesthetic doses, produces systemic analgesia in chronic pain settings, an action largely attributed to block of N-methyl-D-aspartate receptors in the spinal cord and inhibition of central sensitization processes. N-methyl-D-aspartate receptors also are located peripherally on sensory afferent nerve endings, and this provided the initial impetus for exploring peripheral applications of ketamine. Ketamine also produces several other pharmacological actions (block of ion channels and receptors, modulation of transporters, anti-inflammatory effects), and while these may require higher concentrations, after topical (e.g., as gels, creams) and peripheral application (e.g., localized injections), local tissue concentrations are higher than those after systemic administration and can engage lower affinity mechanisms. Peripheral administration of ketamine by localized injection produced some alterations in sensory thresholds in experimental trials in volunteers and in complex regional pain syndrome subjects in experimental settings, but many variables were unaltered. There are several case reports of analgesia after topical application of ketamine given alone in neuropathic pain, but controlled trials have not confirmed such effects. A combination of topical ketamine with several other agents produced pain relief in case, and case series, reports with response rates of 40% to 75% in retrospective analyses. In controlled trials of neuropathic pain with topical ketamine combinations, there were improvements in some outcomes, but optimal dosing and drug combinations were not clear. Given orally (as a gargle, throat swab, localized peritonsillar injections), ketamine produced significant oral/throat analgesia in controlled trials in postoperative settings. Topical analgesics are likely more effective in particular conditions (patient factors, disease factors), and future trials of topical ketamine should include a consideration of factors that could predispose to favorable outcomes.
亚麻醉剂量的氯胺酮在慢性疼痛情况下可产生全身镇痛作用,这一作用很大程度上归因于脊髓中N-甲基-D-天冬氨酸受体的阻断以及中枢敏化过程的抑制。N-甲基-D-天冬氨酸受体也位于感觉传入神经末梢的外周,这为探索氯胺酮的外周应用提供了最初的动力。氯胺酮还产生其他几种药理作用(离子通道和受体的阻断、转运体的调节、抗炎作用),虽然这些可能需要更高的浓度,但在局部应用(如制成凝胶、乳膏)和外周给药(如局部注射)后,局部组织浓度高于全身给药后的浓度,并且可以激活低亲和力机制。在志愿者的实验试验以及实验环境中的复杂性区域疼痛综合征受试者中,通过局部注射外周给予氯胺酮会使感觉阈值发生一些改变,但许多变量未改变。有几例关于单独局部应用氯胺酮治疗神经性疼痛后镇痛的病例报告,但对照试验尚未证实此类效果。局部应用氯胺酮与其他几种药物联合在病例和病例系列报告中产生了疼痛缓解,回顾性分析中的缓解率为40%至75%。在局部应用氯胺酮联合治疗神经性疼痛的对照试验中,一些结果有所改善,但最佳剂量和药物组合尚不清楚。口服氯胺酮(如含漱、咽喉擦拭、扁桃体周围局部注射)在术后环境的对照试验中产生了显著的口腔/咽喉镇痛作用。局部镇痛药可能在特定条件下(患者因素、疾病因素)更有效,未来局部应用氯胺酮的试验应考虑可能有利于取得良好结果的因素。